ArticleMolecular immunology2014
Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.
Article in Molecular immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy.International journal of molecular sciences · 2022Pooled it
- Uveal melanoma: A review of current treatment limitations and the emerging therapeutic potential of natural killer cells.The Journal of investigative dermatology · 2026Review
- Exosome-Based Approaches in Regenerative Medicine and Targeted Therapy for Eye Malignancies: A Comprehensive Review.Eye and brain · 2026Review
- MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review.Diagnostics (Basel, Switzerland) · 2025Review
- Role of miRNA in adult ocular tumorigenesis.Frontiers in molecular biosciences · 2025Review
- Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives.Biomedicines · 2024Review
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- Liquid biopsy for diagnostic and prognostic evaluation of melanoma.Frontiers in cell and developmental biology · 2024Review
- Forces at play: exploring factors affecting the cancer metastasis.Frontiers in immunology · 2024Review
- Determination of Common microRNA Biomarker Candidates in Stage IV Melanoma Patients and a Human Melanoma Cell Line: A Potential Anti-Melanoma Agent Screening Model.International journal of molecular sciences · 2023Article
- A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival.BMC cancer · 2023Article
- Macrophage Reprogramming with Anti-miR223-Loaded Artificial Protocells Enhances In Vivo Cancer Therapeutic Potential.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Future perspectives of uveal melanoma blood based biomarkers.British journal of cancer · 2022Review
- Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma.Biomedicines · 2022Review
- MiRNAs from serum-derived extracellular vesicles as biomarkers for uveal melanoma progression.Frontiers in cell and developmental biology · 2022Article
- Review
- Review
- MiRNAs Correlate with HLA Expression in Uveal Melanoma: Both Up- and Downregulation Are Related to Monosomy 3.Cancers · 2021Article
- Proteomics of Primary Uveal Melanoma: Insights into Metastasis and Protein Biomarkers.Cancers · 2021Article
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe immune response has been implicated in the control of uveal melanoma progression. Epigenetic mechanisms mediated by specific microRNAs (miRs) regulate immune responses.
methodsBlood was drawn from six patients with uveal melanoma followed from diagnosis, at which time there was no clinical or radiographic evidence of metastasis, until metastasis manifested. Circulating T cell, natural killer (NK), natural killer T (NKT), and myeloid suppressor cell populations were assessed by flow cytometry. CD3(+), CD15(+), and CD56(+) cells were isolated using immunomagnetic beads. Plasma and cellular levels of immune regulatory miRs were determined by quantitative polymerase chain reaction assays.
resultsThe development of metastasis was associated with decreases in circulating CD3(-)CD56(dim) NK cells and CD8(+) and double-negative CD3(+)CD56(+) NKT cells. ICOS(+)CD4(+)FoxP3(+) T regulatory cells and CD11b(+)CD14(-)CD15(+) myeloid suppressor cells increased. Plasma levels of miR-20a, 125b, 146a, 155, 181a, and 223 were higher in the study patients at diagnosis compared to controls. Plasma levels of miR-20a, 125b, 146a, 155, and 223 increased, and miR-181a decreased when metastasis manifested. Alterations in immune regulatory miRs were also observed in CD3(+), CD15(+), and CD56(+) cell populations.
conclusionsThe development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.